Krypton Street's Next Profile Just Announced! Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Needs to be #1 on Today's Watchlist! Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Comes Backed with Several Potential Catalysts Including: Recent Market Recognition: Shares Up 93% In Less Than A Month, From $.48 On July 3 To $.93! Bullish Momentum: Shares Surpassed All Major Moving Averages, Per Barchart's Analysis! Analyst Coverage: EF Hutton Targets $6.00, Suggesting a 561% Potential Upside! Upcoming FDA Decision On LYMPHIR™: FDA Decision Expected on August 13, 2024! IPO For LYMPHIR™: Planned IPO This Summer Could Boost Funding and Visibility! Positive Phase 3 Results For Mino-Lok®: Positive Topline Results Announced in May 2024! Orphan Designation: LYMPHIR™ Received Orphan Designation, Potentially 12 Years Exclusivity!
August 5, 2024, Dear Reader, The major markets might be red today, but now could be the best time to pull up Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and start your research. Exciting developments from Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)! The shareholders of TenX Keane have approved the merger with Citius Oncology, Inc. As part of this monumental transaction, Citius Pharmaceuticals will receive 65.6M shares of the newly named Citius Oncology, Inc., retaining a dominant 90% control post-transaction. The merged company will be listed on Nasdaq as Citius Oncology, Inc. This merger is expected to advance the commercialization of LYMPHIR, if approved, and foster additional oncology initiatives. With unanimous Board approval, the merger is set to close in the coming weeks, heralding a new era of growth. Pull up Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) right now and see the full announcement here: See the full announcement here But there's no time to waste. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) appears to be gaining significant market recognition as it moved approximately 93% in less than a month, coming off its 52-week low of $.48 on July 3, 2024, reaching $.93 just this past Friday. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) appears to be gaining significant market recognition, moving approximately 93% in less than a month from $.48 on July 3, 2024, to $.93 this past Friday. This bullish momentum has pushed (CTXR) past all major moving averages, according to Barchart's technical analysis tool: 5-Day MA: $.9266 20-Day MA: $.8409 50-Day MA: $.7112 100-Day MA: $.7398 200-Day MA: $.7440 Year-to-Date MA: $.7337
Adding to the excitement, EF Hutton, a prominent Wall Street firm, has initiated coverage of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) with a target of $6.00, suggesting a potential upside of approximately 561% from Friday's $.906 close.
|
Citius Pharmaceuticals has made substantial progress in advancing its late-stage product candidates and achieving key operational milestones. Here are some notable developments: Mino-Lok®: In May 2024, Citius announced positive topline results from the Phase 3 study of Mino-Lok®, an antibiotic lock solution designed to salvage catheters in patients with bloodstream infections. The study met both primary and secondary endpoints with statistical significance. Next steps include preparing a submission to the U.S. FDAand scheduling a Type B meeting. LYMPHIR™: The Biologics License Application (BLA) for LYMPHIR™, a novel IL-2R immunotherapy for treating cutaneous T-cell lymphoma (CTCL), is currently under FDA review, with August 13, 2024, set as the PDUFA target action date. If approved, LYMPHIR™ could potentially receive 12 years of exclusivity as a new biologic. Citius is preparing for the near-term commercialization of LYMPHIR™. LYMPHIR™ has received orphan designation for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Ongoing Phase 1 studies are exploring additional indications for LYMPHIR™. Halo-Lido: Citius completed enrollment in its Phase 2b trial of Halo-Lido (CITI-002), a topical formulation for relieving hemorrhoid symptoms. Positive data from the trial showed a meaningful reduction in symptom severity. The company held an end-of-Phase 2b meeting with the FDA to discuss the next phase of development for Halo-Lido. Operational Achievements Citius Pharmaceuticals has also strengthened its fiscal position and operational capabilities: Capital Structure: In April 2024, Citius completed a $15M registered direct offering, extending the company's ca-sh runway and supporting future growth initiatives. Oncology Spin-Off: Citius plans to form Citius Oncology, Inc., a standalone publicly traded company with LYMPHIR™ as its primary asset. This transaction is pending review by the U.S. Securities and Exchange Commission (SEC) and approval by TenX Keane Acquisition (Nasdaq: TENK) shareholders. National Sales Director: Citius has on-boarded a National Sales Director to recruit and lead the sales organization in preparation for the anticipated launch of LYMPHIR™. Leadership Perspective Leonard Mazur, Chairman and CEO of Citius, emphasized the company's strategic vision and operational achievements: "Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months. Mino-Lok's strong Phase 3 topline results support its potential to become part of the standard of care for treating catheter-related bloodstream infections. For LYMPHIR™, the FDA is currently reviewing our Biologics License Application, with an expected decision on August 13th. We are preparing for near-term commercialization of LYMPHIR if approved. These near-term catalysts should enable the company to optimize its current ca-sh runway, future ca-sh needs, as well as create potential non-dilutive ca-sh opps." Mazur added, "Our primary purpose and mission for these late-stage assets is to provide best-in-class, highly effective treatment options for patients and caregivers. Ultimately, we believe our achievements and milestones offer powerful levers for value creation." Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is at a pivotal point in its journey, with significant near-term milestones and transformative catalysts on the horizon. The company's innovative late-stage product candidates, Mino-Lok and LYMPHIR, are poised to address critical unmet medical needs and offer substantial market potential. With a strong fiscal foundation and strategic operational initiatives, Citius is well-positioned for sustained growth and value creation. Industry stakeholders should keep a close eye on Citius Pharmaceuticals as it continues to advance its pipeline and achieve key milestones in 2024. |
|
No comments:
Post a Comment